Last reviewed · How we verify
NCT06319664
Clinical Outcomes and Decision-making Choice of Skull Base Approaches for Petroclival Meningiomas
trial testing retrosigmoid approach (RSA) in Skull Base Meningioma in 179 participants. Completed in 10 September 2021.
10 August 2021
Quick facts
| Lead sponsor | Xiangya Hospital of Central South University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 179 |
| Start date | 27 May 2021 |
| Primary completion | 10 August 2021 |
| Estimated completion | 10 September 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- retrosigmoid approach (RSA)
- subtemporal transtentorial transpetrosal approach (STTA)
- extended pterional transtentorial approach (EPTA)
- pretemporal trancavernous anterior transpetrosal approach (PTCA)
- presigmoid combined supra-infratentorial approach (PCA)
- inoperable
Conditions studied
- Skull Base Meningioma — all drugs for Skull Base Meningioma →
Sponsor
Xiangya Hospital of Central South University
Who can join
Adults 15 to 73, any sex, with Skull Base Meningioma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Petroclival meningioma (PCM) is a technically challenging lesion. We aimed to analyze the role of various skull base approaches and evaluate the therapeutic outcomes guided by the modified classification. We retrospectively analyzed the clinical characteristics, surgical approaches, outcomes and follow-up data from 179 cases of PCM from January 2011 to December 2020. We modified the previous classification into updated five types with two subtypes: clivus type (CV), petroclival type (PC), petroclivosphenoidal type (PC-S), sphenopetroclival type (S-PC) with two subtypes of S-PC I and S-PC II and central skull base type (CSB). Statistical analysis was performed using IBM SPSS Statistical Package 21.0. The t-test was performed to clinical data comparisons between the two groups and the ANOVA test was used to compare the difference between multiple groups. P \< 0.05 was considered statistically significant.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06319664
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Xiangya Hospital of Central South University trials
Trials by the same sponsor.
- NCT07482670 — Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases · not yet recruiting
- NCT07412223 — Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery · Phase 4 · not yet recruiting
- NCT07369960 — Repetitive Transcranial Magnetic Stimulation Combined With Language Training for Language Disorders in Children With Glo · NA · recruiting
- NCT07369999 — Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemic Stroke · Phase 3 · not yet recruiting
- NCT07309913 — China Atrial Fibrillation With Complex Metabolic Disorder Cohort Study (CAME Cohort) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06319664 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xiangya Hospital of Central South University
- Last refreshed: 20 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06319664.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing